Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Protagonist Therapeutics Inc
(NQ:
PTGX
)
31.71
+0.45 (+1.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
October 25, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...
Via
Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
Exposures
Product Safety
Analyst Ratings For Protagonist Therapeutics
October 12, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
October 13, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
October 13, 2021
MKM Partners raised the price target on Continental Resources, Inc. (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 12, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
October 12, 2021
Evercore ISI Group raised Lear Corporation (NYSE:
Via
Benzinga
46 Biggest Movers From Yesterday
October 12, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...
Via
Benzinga
Exposures
Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 11, 2021
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
October 11, 2021
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ...
Via
Benzinga
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
October 11, 2021
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
28 Stocks Moving In Monday's Mid-Day Session
October 11, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...
Via
Benzinga
Exposures
Product Safety
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
October 11, 2021
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.
Via
InvestorPlace
Exposures
Product Safety
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
October 11, 2021
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies.
Via
Investor's Business Daily
Exposures
Product Safety
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
October 11, 2021
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 11, 2021
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy
October 05, 2021
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock.
Via
InvestorPlace
58 Biggest Movers From Yesterday
September 24, 2021
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362...
Via
Benzinga
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
September 22, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
20 Stocks Moving in Wednesday's Pre-Market Session
September 22, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 21, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...
Via
Benzinga
32 Stocks Moving In Tuesday's Mid-Day Session
September 21, 2021
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk...
Via
Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...
Via
Benzinga
Exposures
COVID-19
48 Biggest Movers From Yesterday
September 21, 2021
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized...
Via
Benzinga
Why Protagonist Therapeutics Stock Plunged Today
September 20, 2021
The FDA has placed a clinical hold on testing of rusfertide.
Via
The Motley Fool
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.